Unknown

Dataset Information

0

Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.


ABSTRACT: Advances in the understanding of the neurobiology of fear extinction have resulted in the development of d-cycloserine (DCS), a partial glutamatergic N-methyl-D-aspartate agonist, as an augmentation strategy for exposure treatment. We review a decade of research that has focused on the efficacy of DCS for augmenting the mechanisms (e.g., fear extinction) and outcome of exposure treatment across the anxiety disorders. Following a series of small-scale studies offering strong support for this clinical application, more recent larger-scale studies have yielded mixed results, with some showing weak or no effects. We discuss possible explanations for the mixed findings, pointing to both patient and session (i.e., learning experiences) characteristics as possible moderators of efficacy, and offer directions for future research in this area. We also review recent studies that have aimed to extend the work on DCS augmentation of exposure therapy for the anxiety disorders to DCS enhancement of learning-based interventions for addiction, anorexia nervosa, schizophrenia, and depression. Here, we attend to both DCS effects on facilitating therapeutic outcomes and additional therapeutic mechanisms beyond fear extinction (e.g., appetitive extinction, hippocampal-dependent learning).

SUBMITTER: Otto MW 

PROVIDER: S-EPMC4808479 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.

Otto Michael W MW   Kredlow M Alexandra MA   Smits Jasper A J JAJ   Hofmann Stefan G SG   Tolin David F DF   de Kleine Rianne A RA   van Minnen Agnes A   Evins A Eden AE   Pollack Mark H MH  

Biological psychiatry 20150925 4


Advances in the understanding of the neurobiology of fear extinction have resulted in the development of d-cycloserine (DCS), a partial glutamatergic N-methyl-D-aspartate agonist, as an augmentation strategy for exposure treatment. We review a decade of research that has focused on the efficacy of DCS for augmenting the mechanisms (e.g., fear extinction) and outcome of exposure treatment across the anxiety disorders. Following a series of small-scale studies offering strong support for this clin  ...[more]

Similar Datasets

| S-EPMC4761449 | biostudies-literature
| S-EPMC3656563 | biostudies-literature
| S-EPMC10032582 | biostudies-literature
| S-EPMC7065156 | biostudies-literature
| S-EPMC3229761 | biostudies-literature
| S-EPMC6473667 | biostudies-literature
| S-EPMC3881222 | biostudies-literature
| S-EPMC4761635 | biostudies-literature
| S-EPMC8023338 | biostudies-literature
| S-EPMC9650617 | biostudies-literature